PeptiDream Announces FDA Approval of IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.） - PDRファーマ株式会社

お知らせ

News Archive

News Archive

Home
News Archive
PeptiDream Announces FDA Approval of IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.）

2025.12.22

PeptiDream Announces FDA Approval of IND Applications for Phase 1 Clinical Trials of 225Ac-PD-32766 and 64Cu-PD-32766 in Patients with Kidney Cancer（PeptiDream Inc.）

PDFファイルを見る

Back to List